ProShare Advisors
NMRA icon

ProShare Advisors’s Neumora Therapeutics NMRA Stock Holding History

ProShare Advisors’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25,738
Closed -$25.7K – 2148
2025
Q1 		$25.7K Sell
25,738
-5,604
-18% -$9.6K ﹤0.01% 2020
2024
Q4 		$332K Sell
31,342
-448
-1% -$5.37K ﹤0.01% 1552
2024
Q3 		$420K Buy
+31,790
New +$371K ﹤0.01% 1248

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ProShare Advisors's NMRA Position: Q2 2025 in Review

ProShare Advisors sold out of Neumora Therapeutics (NMRA) in Q2 2025, closing a stake of 25,738 shares — an estimated $25.7K sold.

ProShare Advisors first reported a position in NMRA in Q3 2024 and held it in 3 quarters. The position peaked at $420K in Q3 2024. 98 funds tracked by Wall St. Rank hold NMRA as of Q2 2025.

  • ProShare Advisors reported no remaining Neumora Therapeutics position as of Q2 2025 after selling out during the quarter.
  • ProShare Advisors sold 25,738 Neumora Therapeutics shares in Q2 2025, an estimated $25.7K.
  • ProShare Advisors first reported a position in Neumora Therapeutics in Q3 2024 and held it in 3 quarters.
  • ProShare Advisors's Neumora Therapeutics position peaked at $420K in Q3 2024.
  • 98 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2025.

Based on ProShare Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.